Email: cspc@cspc.cn
Email: cspc@cspc.cn
June 16, 2023
On May 19, 2023, the national launch conference of Haiyitan® Glumetinib was held in Shanghai, Beijing and Guangzhou synchronously. Glumetinib, the first highly-selective MET inhibitor approved for the full-line treatment of non-small cell lung cancer with MET exon 14 skipping mutation METex14 in China, was successfully launched. Many well-known experts, top KOLs and scholars in the field of lung cancer were invited to witness this exciting moment of the successful launch of Haiyitan®, and share and exchange Chinese experience in the field of abnormal MET.
Academician Ding Jian of the Chinese Academy of Engineering and Academician Yu Jinming, President of Shandong Cancer Hospital, served as the chairmen of the conference. Prof. Huang Cheng from Fujian Cancer Hospital, Prof. Lu Shun from Shanghai Chest Hospital, Prof. Wang Hui from Hunan Cancer Hospital, Prof. Liu Xiaoqing from Chinese PLA General Hospital, Prof. Wu Yilong from Guangdong Provincial People's Hospital, Prof. Zhi Xiuyi from Lung Cancer Diagnosis and Treatment Center of Capital Medical University, and Prof. Zhou Qing from Guangdong Provincial People's Hospital were the presidium members of the conference. Mr. Wang Zhenguo, Executive President of CSPC, and Mr. Dong Ruiping, Chief Executive Officer of Haihe Biopharma, attended the meeting and discussed the R&D and critical research results of Glumetinib, China's self-developed MET inhibitor.
CSPC, an innovative national enterprise integrating R&D, production and sales, has been adhering to the corporate mission of "All for better medicine, All for a healthier world" and promoting the field development with advanced products. Haiyitan® Glumetinib, a new potent and highly-selective MET inhibitor with excellent pharmacokinetic characteristics, will open up a new era of benefiting Chinese patients!
This information is only an objective description of news events of the Company, and shall not be taken as the basis for product recommendation.
